PURPOSE: To examine the California Cancer Registry (CCR) for bladder cancer survival disparities based on race, socioeconomic status (SES), and insurance in California patients. PATIENTS AND METHODS: The CCR was queried for bladder cancer cases in California from 1988 to 2012. The primary outcome was disease-specific survival (DSS), defined as the time interval from date of diagnosis to date of death from bladder cancer. Survival analyses were performed to determine the prognostic significance of racial and socioeconomic factors. RESULTS: A total of 72,452 cases were included (74.5% men, 25.5% women). The median age was 72 years (range, 18-109 years). The racial distribution among the patients was 81% white, 3.8% black, 8.8% Hispanic, 5.2% Asian, and 1.2% from other races. In black patients, tumors presented more frequently with advanced stage and high grade. Medicaid patients tended to be younger and had more advanced-stage, higher-grade tumors compared to patients with Medicare or managed care (P < .0001). Kaplan-Meier analysis demonstrated significantly poorer 5-year DSS in black, low SES, and Medicaid patients (P < .0001). When controlling for stage, grade, age, and gender, multivariate analysis revealed that black race (DSS hazard ratio = 1.295; 95% confidence interval, 1.212-1.384), low SES (DSS hazard ratio = 1.325; 95% confidence interval, 1.259-1.395), and Medicaid insurance (DSS hazard ratio = 1.349; 95% confidence interval, 1.246-1.460) were independent prognostic factors (P < .0001). CONCLUSION: An analysis of the CCR demonstrated that black race, low SES, and Medicaid insurance portend poorer DSS. These findings reflect a multifaceted socioeconomic and public health conundrum, and efforts to reduce inequalities should be pursued.
PURPOSE: To examine the California Cancer Registry (CCR) for bladder cancer survival disparities based on race, socioeconomic status (SES), and insurance in Californiapatients. PATIENTS AND METHODS: The CCR was queried for bladder cancer cases in California from 1988 to 2012. The primary outcome was disease-specific survival (DSS), defined as the time interval from date of diagnosis to date of death from bladder cancer. Survival analyses were performed to determine the prognostic significance of racial and socioeconomic factors. RESULTS: A total of 72,452 cases were included (74.5% men, 25.5% women). The median age was 72 years (range, 18-109 years). The racial distribution among the patients was 81% white, 3.8% black, 8.8% Hispanic, 5.2% Asian, and 1.2% from other races. In black patients, tumors presented more frequently with advanced stage and high grade. Medicaid patients tended to be younger and had more advanced-stage, higher-grade tumors compared to patients with Medicare or managed care (P < .0001). Kaplan-Meier analysis demonstrated significantly poorer 5-year DSS in black, low SES, and Medicaid patients (P < .0001). When controlling for stage, grade, age, and gender, multivariate analysis revealed that black race (DSS hazard ratio = 1.295; 95% confidence interval, 1.212-1.384), low SES (DSS hazard ratio = 1.325; 95% confidence interval, 1.259-1.395), and Medicaid insurance (DSS hazard ratio = 1.349; 95% confidence interval, 1.246-1.460) were independent prognostic factors (P < .0001). CONCLUSION: An analysis of the CCR demonstrated that black race, low SES, and Medicaid insurance portend poorer DSS. These findings reflect a multifaceted socioeconomic and public health conundrum, and efforts to reduce inequalities should be pursued.
Authors: Andrew G Bachman; Alexander A Parker; Marshall D Shaw; Brian W Cross; Kelly L Stratton; Michael S Cookson; Sanjay G Patel Journal: Urology Date: 2017-02-15 Impact factor: 2.649
Authors: Karla J Lindquist; Pamela L Paris; Thomas J Hoffmann; Niall J Cardin; Rémi Kazma; Joel A Mefford; Jeffrey P Simko; Vy Ngo; Yalei Chen; Albert M Levin; Dhananjay Chitale; Brian T Helfand; William J Catalona; Benjamin A Rybicki; John S Witte Journal: Cancer Res Date: 2016-02-26 Impact factor: 12.701
Authors: Stephen B Williams; Jinhai Huo; Karim Chamie; Jim C Hu; Sharon H Giordano; Karen E Hoffman; Colin P N Dinney; Ashish M Kamat; Ya-Chen Tina Shih Journal: Eur Urol Focus Date: 2016-05-13
Authors: G R Prout; M N Wesley; R S Greenberg; V W Chen; C C Brown; A W Miller; R S Weinstein; S J Robboy; M A Haynes; R S Blacklow; B K Edwards Journal: Cancer Date: 2000-09-15 Impact factor: 6.860
Authors: Elizabeth Ward; Michael Halpern; Nicole Schrag; Vilma Cokkinides; Carol DeSantis; Priti Bandi; Rebecca Siegel; Andrew Stewart; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2007-12-20 Impact factor: 508.702
Authors: Kimberly D Miller; Rebecca L Siegel; Chun Chieh Lin; Angela B Mariotto; Joan L Kramer; Julia H Rowland; Kevin D Stein; Rick Alteri; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2016-06-02 Impact factor: 508.702
Authors: Ian J Cooke; Dattatraya Patil; Katherine Bobrek; Vikram Narayan; Viraj Master; Mark Rapaport; Christopher P Filson; Shreyas S Joshi Journal: Cancer Med Date: 2021-11-12 Impact factor: 4.452
Authors: Florian Janisch; Hang Yu; Malte W Vetterlein; Roland Dahlem; Oliver Engel; Margit Fisch; Shahrokh F Shariat; Armin Soave; Michael Rink Journal: J Clin Med Date: 2019-09-13 Impact factor: 4.241
Authors: Dylan T Wolff; Thomas F Monaghan; Danielle J Gordon; Kyle P Michelson; Tashzna Jones; Raymond Khargi; Matthew T Smith; Fenizia Maffucci; Hyezo Kwun; Nicholas R Suss; Andrew G Winer Journal: Medicina (Kaunas) Date: 2021-06-29 Impact factor: 2.430